Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

  • 33 views
  • 07 Oct, 2022
  • 152 locations
A Phase II, Multicenter, Randomized, Double Masked, Active Comparator-Controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 in Combination With Ranibizumab Administered Intravitreally in Patients With Diabetic Macular Edema

pharmacodynamics (PD) of RO7200220 in combination with, anti-vascular endothelial growth factor (VEGF) inhibitor, ranibizumab compared with ranibizumab alone in participants with diabetic macular edema. Only one

  • 1 views
  • 23 Oct, 2022
  • 37 locations
  • 0 views
  • 16 Oct, 2022
  • 80 locations
A Phase IIIb, Multicenter, Randomized, Visual Assessor-Masked Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration (Diagrid)

This study will evaluate the effectiveness and safety of a 36-week refill regimen for the Port Delivery System with ranibizumab 100 mg/mL (PDS Q36W) compared with intravitreal injections of

  • 1 views
  • 25 Oct, 2022
  • 9 locations
Combination of Ranibizumab and Targeted Laser Photocoagulation (CoRaLaII)

Intravitreal injections of Ranibizumab will be applied in all patients according to treatment guidelines. The experimental group will receive additional targeted laser photocoagulation of the

  • 60 views
  • 24 May, 2022
  • 11 locations
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV

  • 0 views
  • 23 Jun, 2021
  • 1 location
  • 0 views
  • 14 Oct, 2022
  • 32 locations
Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

this study will compare the efficacy and safety of HLX04-O administered by IVT with ranibizumab in patients with active CNV secondary to AMD.

vegf
diabetic retinopathy
retinopathy
vascular endothelial growth factor
lucentis
  • 0 views
  • 16 May, 2022
  • 41 locations
A Phase 3 Two-part Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.

angiography
wet age-related macular degeneration
fluorescein angiography
vegf
diabetic retinopathy
  • 22 views
  • 07 Oct, 2022
  • 1 location
  • 0 views
  • 07 Oct, 2022
  • 1 location